PATENT CLAIM ANALYSIS

Application Number: 15762238
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "001100"]

Abstract:
The present invention provides 75 kD transmembrane neurotrophin receptor (p75 NTR ) antagonists and their use in prevention and treatment of loss of function, and adverse remodeling, in cardiac tissues subject to acute or chronic hemodynamic stress. Uses of the antagonists with or without additional cardiotropic agents for improving contractility and for treatment of congestive heart failure are also provided.

Claim (Index 4):
The pharmaceutical composition of  claim 4 , wherein the cardiotropic agent is selected from the group consisting of cardiac glycosides, \u03b2-blockers, calcium channel blockers, nitrates, class I antiarrhythmics, class antiarrhythmics II, angiotensin-converting enzyme inhibitor (ACE inhibitor) antihypertensives, central-acting adrenergic antihypertensives, diuretic antihypertensive agents, and peripheral vasodilator antihypertensives.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 90.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13879226', '15135774', '15804339', '11722915', '12915352']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7669466753960021
- 35 USC 102 Novelty (BERT): 0.4990823643608593
- Combined Prediction Score: 0.740160244292488
- Mean Citation Score: 190.191454
- Max Citation Score: 194.68834
- Similarity Product: 120.02202346220255

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test